View Item 

Show simple item record

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
dc.contributor.authorKoshkin, Vadim S.
dc.contributor.authorHenderson, Nicholas
dc.contributor.authorJames, Marihella
dc.contributor.authorNatesan, Divya
dc.contributor.authorFreeman, Dory
dc.contributor.authorNizam, Amanda
dc.contributor.authorSu, Christopher T.
dc.contributor.authorKhaki, Ali Raza
dc.contributor.authorOsterman, Chelsea K.
dc.contributor.authorGlover, Michael J.
dc.contributor.authorChiang, Ryan
dc.contributor.authorMakrakis, Dimitrios
dc.contributor.authorTalukder, Rafee
dc.contributor.authorLemke, Emily
dc.contributor.authorOlsen, T. Anders
dc.contributor.authorJain, Jayanshu
dc.contributor.authorJang, Albert
dc.contributor.authorAli, Alicia
dc.contributor.authorJindal, Tanya
dc.contributor.authorChou, Jonathan
dc.contributor.authorFriedlander, Terence W.
dc.contributor.authorHoimes, Christopher
dc.contributor.authorBasu, Arnab
dc.contributor.authorZakharia, Yousef
dc.contributor.authorBarata, Pedro C.
dc.contributor.authorBilen, Mehmet A.
dc.contributor.authorEmamekhoo, Hamid
dc.contributor.authorDavis, Nancy B.
dc.contributor.authorShah, Sumit A.
dc.contributor.authorMilowsky, Matthew I.
dc.contributor.authorGupta, Shilpa
dc.contributor.authorCampbell, Matthew T.
dc.contributor.authorGrivas, Petros
dc.contributor.authorSonpavde, Guru P.
dc.contributor.authorKilari, Deepak
dc.contributor.authorAlva, Ajjai S.
dc.date.accessioned2022-03-07T03:12:30Z
dc.date.available2023-04-06 22:12:29en
dc.date.available2022-03-07T03:12:30Z
dc.date.issued2022-03-15
dc.identifier.citationKoshkin, Vadim S.; Henderson, Nicholas; James, Marihella; Natesan, Divya; Freeman, Dory; Nizam, Amanda; Su, Christopher T.; Khaki, Ali Raza; Osterman, Chelsea K.; Glover, Michael J.; Chiang, Ryan; Makrakis, Dimitrios; Talukder, Rafee; Lemke, Emily; Olsen, T. Anders; Jain, Jayanshu; Jang, Albert; Ali, Alicia; Jindal, Tanya; Chou, Jonathan; Friedlander, Terence W.; Hoimes, Christopher; Basu, Arnab; Zakharia, Yousef; Barata, Pedro C.; Bilen, Mehmet A.; Emamekhoo, Hamid; Davis, Nancy B.; Shah, Sumit A.; Milowsky, Matthew I.; Gupta, Shilpa; Campbell, Matthew T.; Grivas, Petros; Sonpavde, Guru P.; Kilari, Deepak; Alva, Ajjai S. (2022). "Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study." Cancer (6): 1194-1205.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/171856
dc.publisherWiley Periodicals, Inc.
dc.subject.otherantibody‐drug conjugate
dc.subject.otherurinary bladder
dc.subject.otherurothelial cancer
dc.subject.othernectin‐4
dc.subject.otherenfortumab vedotin
dc.subject.otherbladder cancer
dc.titleEfficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171856/1/cncr34057_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171856/2/cncr34057.pdf
dc.identifier.doi10.1002/cncr.34057
dc.identifier.sourceCancer
dc.identifier.citedreferenceTeo MY, Ratna N, Regazzi AM, et al. Enfortumab vedotin in FGFR3‐mutated advanced urothelial carcinoma. J Clin Oncol. 2021; 39 ( suppl ): 458.
dc.identifier.citedreferenceKim K, Hu W, Audenet F, et al. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nat Commun. 2020; 11: 1975.
dc.identifier.citedreferenceHoffman‐Censits JH, Lombardo KA, Parimi V, et al. Expression of nectin‐4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol. 2021; 29: 619 ‐ 625.
dc.identifier.citedreferenceHoffman‐Censits JH, Choi W, Lombardo K, et al. Expression of nectin‐4 in bladder cancer with variant histology. J Clin Oncol. 2020; 38 ( suppl ): 546.
dc.identifier.citedreferenceTagawa ST, Balar AV, Petrylak DP, et al. TROPHY‐U‐01: a phase II open‐label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum‐based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021; 39: 2474 ‐ 2485.
dc.identifier.citedreferenceSiefker‐Radtke AO, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC): long‐term outcomes in BLC2001. J Clin Oncol. 2020; 38: 5015.
dc.identifier.citedreferenceBalar AV, McGregor BA, Rosenberg JE, et al. EV‐201 cohort 2: enfortumab vedotin in cisplatin‐ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD‐1/PD‐L1 inhibitors. J Clin Oncol. 2021; 39 ( suppl ): 394.
dc.identifier.citedreferenceEisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228 ‐ 247.
dc.identifier.citedreferenceHarris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42: 377 ‐ 381.
dc.identifier.citedreferenceChu CE, Sjöström M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021; 27: 5123.
dc.identifier.citedreferenceRosenberg JE, Flaig TW, Friedlander TW, et al. Study EV‐103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2020; 38 ( suppl ): 441.
dc.identifier.citedreferencePowles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021; 384: 1125 ‐ 1135.
dc.identifier.citedreferenceRosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti–programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019; 37: 2592 ‐ 2600.
dc.identifier.citedreferenceHeath EI, Rosenberg JE. The biology and rationale of targeting nectin‐4 in urothelial carcinoma. Nat Rev Urol. 2021; 18: 93 ‐ 103.
dc.identifier.citedreferenceRosenberg J, Sridhar SS, Zhang J, et al. EV‐101: a phase I study of single‐agent enfortumab vedotin in patients with nectin‐4–positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020; 38: 1041 ‐ 1049.
dc.identifier.citedreferenceChallita‐Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody‐drug conjugate targeting nectin‐4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016; 76: 3003 ‐ 3013.
dc.identifier.citedreferenceBalar AV, Castellano D, O’Donnell PH, et al. First‐line pembrolizumab in cisplatin‐ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE‐052): a multicentre, single‐arm, phase 2 study. Lancet Oncol. 2017; 18: 1483 ‐ 1492.
dc.identifier.citedreferenceBalar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first‐line treatment in cisplatin‐ineligible patients with locally advanced and metastatic urothelial carcinoma: a single‐arm, multicentre, phase 2 trial. Lancet. 2017; 389: 67 ‐ 76.
dc.identifier.citedreferenceSternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high‐dose‐intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony‐stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19: 2638 ‐ 2646.
dc.identifier.citedreferenceRosenberg JE, Hoffman‐Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. Lancet. 2016; 387: 1909 ‐ 1920.
dc.identifier.citedreferenceSternberg CN, Yagoda A, Scher HI, et al. M‐VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988; 139: 461 ‐ 469.
dc.identifier.citedreferencePowles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020; 383: 1218 ‐ 1230.
dc.identifier.citedreferenceBellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 1015 ‐ 1026.
dc.identifier.citedreferencevon der Maase H, Sengelov L, Roberts JT, et al. Long‐term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602 ‐ 4608.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34057_am.pdf
Size:
414.8KB
Format:
PDF
View/Open
Name:
cncr34057.pdf
Size:
450.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.